ArticleJournal of biomedical optics2012
Investigating photoexcitation-induced mitochondrial damage by chemotherapeutic corroles using multimode optical imaging.
Article in Journal of biomedical optics, 2012. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
10 citing papers in PubMed.
- Next generation protein-corrole bio-assemblies provide effective tumoricidal treatment in a metastatic triple-negative breast cancer model.bioRxiv : the preprint server for biology · 2026Article
- The role of corroles in modern cancer therapy: innovation and prospects.Biometals : an international journal on the role of metal ions in biology, biochemistry, and medicine · 2025Review
- Biomedical Applications of Translational Optical Imaging: From Molecules to Humans.Molecules (Basel, Switzerland) · 2021Review
- Ultrafast Dynamics of Sb-Corroles: A Combined Vis-Pump Supercontinuum Probe and Broadband Fluorescence Up-Conversion Study.Molecules (Basel, Switzerland) · 2017Article
- Ultrafast electronic and vibrational dynamics in brominated aluminum corroles: Energy relaxation and triplet formation.Structural dynamics (Melville, N.Y.) · 2016Article
- A corrole nanobiologic elicits tissue-activated MRI contrast enhancement and tumor-targeted toxicity.Journal of controlled release : official journal of the Controlled Release Society · 2015Article
- An in vitro enzymatic assay to measure transcription inhibition by gallium(III) and H3 5,10,15-tris(pentafluorophenyl)corroles.Journal of visualized experiments : JoVE · 2015Article
- Development of adenovirus capsid proteins for targeted therapeutic delivery.Therapeutic delivery · 2013Review
- Photoexcitation of tumor-targeted corroles induces singlet oxygen-mediated augmentation of cytotoxicity.Journal of controlled release : official journal of the Controlled Release Society · 2012Article
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
We recently reported that a targeted, brightly fluorescent gallium corrole (HerGa) is highly effective for breast tumor detection and treatment. Unlike structurally similar porphryins, HerGa exhibits tumor-targeted toxicity without the need for photoexcitation. We have now examined whether photoexcitation further modulates HerGa toxicity, using multimode optical imaging of live cells, including two-photon excited fluorescence, differential interference contrast (DIC), spectral, and lifetime imaging. Using two-photon excited fluorescence imaging, we observed that light at specific wavelengths augments the HerGa-mediated mitochondrial membrane potential disruption of breast cancer cells in situ. In addition, DIC, spectral, and fluorescence lifetime imaging enabled us to both validate cell damage by HerGa photoexcitation and investigate HerGa internalization, thus allowing optimization of light dose and timing. Our demonstration of HerGa phototoxicity opens the way for development of new methods of cancer intervention using tumor-targeted corroles.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.